Solid Biosciences Inc. (SLDB)
Upgrades & Downgrades
Latest SLDB news
Solid Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
9 January 2023
CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced ...
Solid Biosciences Inc. (SLDB) Reports Q3 Loss, Lags Revenue Estimates
10 November 2022
Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of -4.63% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stoc...
7 Sizzling Stocks That Are Oblivious to the Manic Market
20 October 2022
It's a scientific reality that people don't operate well when they are anxious, but it also sets up an intriguing opportunity for sizzling stocks to buy. Essentially, with many investors panicking out...
Solid Biosciences Inc. (SLDB) CEO Ilan Ganot on Q1 2022 Results - Earnings Call Transcript
30 April 2022
Solid Biosciences Inc. (NASDAQ:SLDB ) Q1 2022 Results Conference Call April 27, 2022 8:00 AM ET Company Participants Caitlin Lowie - VP, Communications and IR Ilan Ganot - Co-Founder, President and CE...
Solid Biosciences Inc. (SLDB) Reports Q1 Loss, Misses Revenue Estimates
27 April 2022
Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of -22.22% and 46.08%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock...
Solid Biosciences Posts Two-Year Efficacy, Safety Data From Duchenne Gene Therapy Trial
14 March 2022
Solid Biosciences Inc (NASDAQ: SLDB) has reported two-year interim efficacy and safety data from the first three patients treated with SGT-001 in the high dose (2E14 vg/kg) cohort as part of IGNITE DM...
Solid Biosciences to Participate at the SVB Leerink 11th Annual Global Healthcare Conference
10 February 2022
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne),...
All You Need to Know About Solid Biosciences Inc. (SLDB) Rating Upgrade to Buy
5 January 2022
Solid Biosciences Inc. (SLDB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
5 Short Squeeze Penny Stocks To Buy For Under $5 Right Now
5 November 2021
5 short squeeze penny stocks to buy for under $5. Are they worth the risk?